Cholinergic and adrenergic activating agents as antagonists of the EEG effects of hemicholinium-3.
D000109:Acetylcholine / Q000378:metabolism*; D000661:Amphetamine / Q000494:pharmacology; D000772:Anesthesia, Local; D000818:Animals; D001713:Biphenyl Compounds / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects*; D001923:Brain Chemistry / Q000187:drug effects; D003650:Decamethonium Compounds; D004285:Dogs; D004336:Drug Antagonism; D004569:Electroencephalography; D004837:Epinephrine / Q000494:pharmacology; D005730:Ganglionic Blockers / Q000494:pharmacology*; D009538:Nicotine / Q000494:pharmacology; D009539:Nicotinic Acids / Q000494:pharmacology; D010277:Parasympathomimetics / Q000494:pharmacology*; D010830:Physostigmine / Q000494:pharmacology; D010862:Pilocarpine / Q000494:pharmacology; D012121:Respiration, Artificial; D013566:Sympathomimetics / Q000494:pharmacology*
D001713:Biphenyl Compounds; D003650:Decamethonium Compounds; D005730:Ganglionic Blockers; D009539:Nicotinic Acids; D010277:Parasympathomimetics; D013566:Sympathomimetics; D010862:Pilocarpine; D009538:Nicotine; D010830:Physostigmine; D000661:Amphetamine; D000109:Acetylcholine; D004837:Epinephrine